Serum HBsAg clearance has minimal impact on CD8+ T cell responses in mouse models of HBV infection
Open Access
- 5 August 2020
- journal article
- research article
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 217 (11)
Abstract
Antibody-mediated clearance of hepatitis B surface antigen (HBsAg) from the circulation of chronically infected patients (i.e., seroconversion) is usually associated with increased HBV-specific T cell responsiveness. However, a causative link between serum HBsAg levels and impairment of intrahepatic CD8+ T cells has not been established. Here we addressed this issue by using HBV replication-competent transgenic mice that are depleted of circulating HBsAg, via either spontaneous seroconversion or therapeutic monoclonal antibodies, as recipients of HBV-specific CD8+ T cells. Surprisingly, we found that serum HBsAg clearance has only a minimal effect on the expansion of HBV-specific naive CD8+ T cells undergoing intrahepatic priming. It does not alter their propensity to become dysfunctional, nor does it enhance the capacity of IL-2–based immunotherapeutic strategies to increase their antiviral function. In summary, our results reveal that circulating HBsAg clearance does not improve HBV-specific CD8+ T cell responses in vivo and may have important implications for the treatment of chronic HBV infection.Keywords
Funding Information
- European Research Council (725038, 957502)
- Italian Association for Cancer Research (19891, 22737)
- Italian Ministry of Health (RF-2018-12365801)
- Lombardy Foundation for Biomedical Research (2015-0010)
- European Molecular Biology Organization
- Gilead Sciences
- Italian Association for Cancer Research (22737)
- Lombardy Open Innovation (229452)
- Italian Ministry of Education, University and Research (2017MPCWPY)
- Gilead Sciences
This publication has 30 references indexed in Scilit:
- Bisphosphonates Target B Cells to Enhance Humoral Immune ResponsesCell Reports, 2013
- CD40 Activation Rescues Antiviral CD8+ T Cells from PD-1-Mediated ExhaustionPLOS Pathogens, 2013
- A Vesicular Stomatitis Virus-Based Therapeutic Vaccine Generates a Functional CD8 T Cell Response to Hepatitis B Virus in Transgenic MiceJournal of Virology, 2013
- Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis BProceedings of the National Academy of Sciences, 2012
- Novel Mechanism of Antibodies to Hepatitis B Virus in Blocking Viral Particle Release from Cells†Hepatology, 2010
- IMMUNOBIOLOGY AND PATHOGENESIS OF VIRAL HEPATITISAnnual Review of Pathology: Mechanisms of Disease, 2006
- Clinical evaluation (phase I) of a combination of two human monoclonal antibodies to HBV: Safety and antiviral propertiesHepatology, 2002
- Preclinical Evaluation of Two Human Anti-Hepatitis B Virus (HBV) Monoclonal Antibodies in the HBV-Trimera Mouse Model and in HBV Chronic Carrier ChimpanzeesHepatology, 2000
- Intracellular Inactivation of the Hepatitis B Virus by Cytotoxic T LymphocytesImmunity, 1996
- Purification and Biophysical Characterization of Hepatitis B AntigenJournal of Clinical Investigation, 1973